Wanbangde Pharmaceutical Holding Group Co Ltd (002082) — Strategic Asset Allocation Index
Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has a Strategic Asset Allocation Index of 51.4% as of June 2023. Strategic assets (PP&E of CN¥1.42 Billion plus long-term investments of CN¥-) total CN¥1.42 Billion, measured against net assets of CN¥2.77 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See 002082 equity financing ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Wanbangde Pharmaceutical Holding Group Co Ltd Strategic Asset Allocation Index (2003–2021)
This chart shows how Wanbangde Pharmaceutical Holding Group Co Ltd's Strategic Asset Allocation Index has evolved across 19 annual periods from 2003 to 2021. As of June 2023, the index stands at 51.4%, representing strategic assets of CN¥1.42 Billion against net assets of CN¥2.77 Billion CNY. For live market cap and overall valuation, see 002082 company net worth.
Annual Strategic Asset Allocation Index for Wanbangde Pharmaceutical Holding Group Co Ltd (2003–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Wanbangde Pharmaceutical Holding Group Co Ltd from 2003 to 2021, covering 19 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Wanbangde Pharmaceutical Holding Group C (002082) net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 42.8% | CN¥1.18 Billion | CN¥1.18 Billion | CN¥- | CN¥2.74 Billion | ▼ -18.0 pp |
| 2020 | 60.8% | CN¥1.74 Billion | CN¥1.74 Billion | CN¥- | CN¥2.86 Billion | ▼ -3.7 pp |
| 2019 | 64.5% | CN¥1.23 Billion | CN¥1.23 Billion | CN¥- | CN¥1.91 Billion | ▲ +48.4 pp |
| 2018 | 16.2% | CN¥278.60 Million | CN¥278.60 Million | CN¥- | CN¥1.72 Billion | ▼ -15.6 pp |
| 2017 | 31.8% | CN¥509.95 Million | CN¥509.95 Million | CN¥- | CN¥1.60 Billion | ▲ +2.9 pp |
| 2016 | 28.9% | CN¥403.55 Million | CN¥403.55 Million | CN¥- | CN¥1.40 Billion | ▼ -4.6 pp |
| 2015 | 33.5% | CN¥451.11 Million | CN¥451.11 Million | CN¥- | CN¥1.35 Billion | ▼ -2.2 pp |
| 2014 | 35.7% | CN¥462.27 Million | CN¥462.27 Million | CN¥- | CN¥1.30 Billion | ▼ -9.3 pp |
| 2013 | 45.0% | CN¥534.18 Million | CN¥534.18 Million | CN¥- | CN¥1.19 Billion | ▼ -10.0 pp |
| 2012 | 55.0% | CN¥603.37 Million | CN¥603.37 Million | CN¥- | CN¥1.10 Billion | ▼ -3.7 pp |
| 2011 | 58.7% | CN¥618.82 Million | CN¥618.82 Million | CN¥- | CN¥1.05 Billion | ▼ -0.6 pp |
| 2010 | 59.3% | CN¥555.12 Million | CN¥555.12 Million | CN¥- | CN¥936.13 Million | ▼ -13.2 pp |
| 2009 | 72.5% | CN¥588.26 Million | CN¥588.26 Million | CN¥- | CN¥811.59 Million | ▼ -6.7 pp |
| 2008 | 79.2% | CN¥563.86 Million | CN¥563.86 Million | CN¥- | CN¥712.31 Million | ▼ -28.9 pp |
| 2007 | 108.1% | CN¥448.58 Million | CN¥448.58 Million | CN¥- | CN¥415.12 Million | ▲ +9.8 pp |
| 2006 | 98.3% | CN¥351.63 Million | CN¥351.63 Million | CN¥- | CN¥357.72 Million | ▼ -103.2 pp |
| 2005 | 201.5% | CN¥308.10 Million | CN¥308.10 Million | CN¥- | CN¥152.88 Million | ▲ +33.5 pp |
| 2004 | 168.0% | CN¥228.80 Million | CN¥228.80 Million | CN¥- | CN¥136.17 Million | ▲ +29.2 pp |
| 2003 | 138.8% | CN¥136.77 Million | CN¥136.77 Million | CN¥- | CN¥98.53 Million | — |